SEC Comment Letter for BIOCRYST PHARMACEUTICALS (BCRX) — Jan 18, 2022

BIOCRYST PHARMACEUTICALS INC
Date: Jan. 18, 2022 · CIK: 0000882796 · Accession: 0000000000-22-000611

View on Edgar

AI Filing Summary & Sentiment

Sentiment

Urgency

Document Type

Confidence

SEC Posture

Company Posture

Summary

Reasoning

File numbers found in text: 000-23186

Date

January 18, 2022

Author

Alane Barnes

Form

UPLOAD

Company

BIOCRYST PHARMACEUTICALS INC

Letter

United States securities and exchange commission logo January 18, 2022 Alane Barnes Chief Legal Officer BioCryst Pharmaceuticals, Inc. 4505 Emperor Blvd., Suite 200 Durham, North Carolina 27703 Re:BioCryst Pharmaceuticals, Inc. Form 10-K for the Fiscal Year Ended December 31, 2020 Filed March 1, 2021 File No. 000-23186 Dear Ms. Barnes: We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text

United States securities and exchange commission logo
January 18, 2022
Alane Barnes
Chief Legal Officer
BioCryst Pharmaceuticals, Inc.
4505 Emperor Blvd., Suite 200
Durham, North Carolina 27703
Re:BioCryst Pharmaceuticals, Inc.
Form 10-K for the Fiscal Year Ended December 31, 2020
Filed March 1, 2021
File No. 000-23186
Dear Ms. Barnes:
            We have completed our review of your filing.  We remind you that the company and its
management are responsible for the accuracy and adequacy of their disclosures, notwithstanding
any review, comments, action or absence of action by the staff.
Sincerely,
Division of Corporation Finance
Office of Life Sciences

SecProbe.io